Why is GHRP-6 still used when ipamorelin exists?

GHRP-6 has the deepest research base of any GH secretagogue (778 published studies) and unique cardioprotective research that ipamorelin lacks. For clinical GH optimization, ipamorelin is generally preferred. For research applications and specific contexts where appetite stimulation is desired, GHRP-6 retains relevance.

Is GHRP-6 FDA-approved?

GHRP-6 is not FDA-approved. It is on the FDA Category 2 compounding list, meaning it can be compounded by pharmacies under specific conditions with a valid prescription.

Does GHRP-6 increase appetite?

Yes. GHRP-6 produces the strongest appetite stimulation of any GH secretagogue through direct ghrelin pathway activation. This is a well-documented, dose-dependent effect that occurs alongside GH release. For some clinical contexts (cachexia, appetite loss), this may be beneficial.

What is the difference between GHRP-6 and GHRP-2?

Both activate the ghrelin receptor to stimulate GH release. GHRP-2 produces slightly stronger GH release with less appetite stimulation and cortisol elevation. GHRP-6 has a deeper research base and unique cardioprotective data. Both are less selective than ipamorelin.

What does the research show about: Bowers et al. (1991): Initial characterization of GHRP-6 as a GH secretagogue, e?

Bowers et al. (1991): Initial characterization of GHRP-6 as a GH secretagogue, establishing the pharmacological basis for the entire GHRP class.. Foundational work that launched GH secretagogue research

What tissue repair evidence exists for this compound?

Berlanga et al. (2007): Demonstrated wound healing and cytoprotective effects with GHRP-6 independent of GH release.. Opened a distinct cardioprotective research line unique to GHRP-6

What does the research show about: Penalva et al. (2008): Documented GH release patterns in human clinical studies,?

Penalva et al. (2008): Documented GH release patterns in human clinical studies, confirming the pharmacological profile across populations.. Clinical validation of the GH secretagogue mechanism in humans

What does the research show about: 778 published studies make GHRP-6 the most extensively researched synthetic GH s?

778 published studies make GHRP-6 the most extensively researched synthetic GH secretagogue.. The deepest evidence base of any compound in its class

reviewed april 2026|next review october 2026|88 physicians psi has verified|778 published studies

GHRP-6

Q: Does GHRP-6 protect the heart?

Preclinical research by Berlanga and colleagues suggests GHRP-6 has cardioprotective effects that operate independently of GH release. This is a preclinical finding that has not been confirmed in human cardiac outcome trials.

GHRP-6 is the founding member of the synthetic growth hormone secretagogue class, first characterized in the 1980s, with 778 published studies representing the deepest evidence base of any GH secretagogue and a secondary cardioprotective research program independent of GH release.

Evidence landscape: 778 published studies

778 published items. 2 human studies indexed for this slug and 195 animal studies. The deepest evidence base of any GH secretagogue, dominated by the animal and mechanistic literature.

2 Human
195 Animal
3 Reviews
578 Other research

First synthetic GH secretagogue characterized in the 1980s. Established the pharmacological framework for the entire GHRP class.

778 published studies - the most extensively researched synthetic GH secretagogue on this platform.

Produces the strongest appetite drive of any GHRP through hypothalamic NPY/AgRP neuron activation. Also elevates cortisol and prolactin.

PSI Assessment

The compound that launched the entire growth hormone secretagogue class in the 1980s remains the most extensively researched synthetic GHRP, with 778 published studies - the deepest evidence base of any GH secretagogue on this platform. GHRP-6 produces the strongest appetite stimulation of any peptide in its class alongside potent GH release, cortisol elevation, and prolactin increase. A separate line of research by Berlanga and colleagues has identified cytoprotective and wound healing effects that appear independent of growth hormone secretion.

778 published studies. The founding member of the GH secretagogue class. The strongest appetite drive of any GHRP, with a separate cardioprotective research line.

The mechanism is ghrelin receptor (GHS-R1a) agonism with the lowest receptor selectivity of any GHRP. GHRP-6 activates hypothalamic NPY/AgRP neurons, driving appetite stimulation stronger than any other compound in the class. It also stimulates ACTH release, causing cortisol elevation, and increases prolactin. The cardioprotective research, primarily by Berlanga and colleagues, has identified PI3K/Akt survival signaling through cardiac GHS-R1a receptors, an effect that appears independent of the GH response.

What the evidence supports

GHRP-6 reliably stimulates GH release through ghrelin receptor activation, documented across the deepest evidence base of any GH secretagogue (778 published studies). It produces the strongest appetite stimulation of any GHRP through NPY/AgRP pathway activation. Cortisol and prolactin co-elevation are well-characterized and the most pronounced in the class. Cardioprotective effects independent of GH release have been documented by Berlanga and colleagues in animal models.

What is not yet established

Whether GH elevation from GHRP-6 produces meaningful body composition or recovery outcomes in controlled trials. Whether the cardioprotective effects translate to human cardiac benefit. Whether the appetite stimulation can be therapeutically leveraged for cachexia. Long-term safety with chronic administration.

Research Evidence

The findings below cover the founding role and evidence depth, the non-selective hormonal profile, and the distinct cardioprotective research line.

Evidence by condition

Evidence dimensions across GHRP-6's investigated conditions. GH stimulation has the deepest human evidence. Cardiac protection is supported by animal studies only.

Condition	Mechanism	Animal evidence	Human evidence	Replication
GH Stimulation
Cardiac Protection
Appetite/GI Function
Body Composition
Neuroprotection

GHRP-6 is the founding member of the synthetic GH secretagogue class (1980s) with 778 published studies - the deepest evidence base of any GH secretagogue. The GH-releasing mechanism through ghrelin receptor activation is well-characterized and reproducible in human studies.

The foundational role means GHRP-6 established the pharmacological framework against which all subsequent GHRPs were evaluated.

GHRP-6 produces the strongest appetite stimulation of any GH secretagogue through direct activation of hypothalamic NPY/AgRP neurons via GHS-R1a. The non-selective profile also elevates cortisol (through CRH neuron activation) and prolactin, both more pronounced than with GHRP-2 or ipamorelin.

The non-selective profile is both the defining characteristic and the primary limitation. For most clinical applications, this side effect profile has led practitioners to prefer ipamorelin or hexarelin.

Berlanga and colleagues have documented cytoprotective and wound healing effects with GHRP-6 that appear independent of GH secretion. The proposed mechanism involves PI3K/Akt survival signaling through cardiac GHS-R1a receptors.

This cardioprotective research line distinguishes GHRP-6 from compounds where the only interest is the GH response. All cardiac data is from animal models (preclinical).

2 Human|195 Animal|3 Reviews

View all 778 indexed studies

How GHRP-6 Works

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide that binds the ghrelin receptor (GHS-R1a) with the lowest selectivity of any GHRP, activating GH release, appetite, cortisol, and prolactin pathways simultaneously.

GHRP-6 works by activating the same receptor that the hunger hormone ghrelin uses. When this receptor is triggered, the pituitary gland releases a burst of growth hormone. But because the ghrelin receptor controls more than just GH release, GHRP-6 also strongly stimulates appetite, raises cortisol (a stress hormone), and increases prolactin. Think of it as pressing a button that turns on several systems at once rather than just the one you want.

For a more detailed view of the biology, here is what researchers have observed at the molecular level.

GHRP-6 binds GHS-R1a in the anterior pituitary and hypothalamus. It stimulates GH release through the phospholipase C/IP3/calcium pathway, complementary to the cAMP pathway used by GHRH. It suppresses somatostatin tone, amplifying the GH pulse. Hypothalamic NPY/AgRP neuron activation drives the strongest appetite stimulation in the GHRP class. CRH neuron activation causes cortisol elevation. Cardiac GHS-R1a activation mediates the Berlanga cardioprotective findings through PI3K/Akt survival signaling.

What is GHRP-6 being studied for?

Researchers are studying GHRP-6 across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for GHRP-6 overall. This means a compound can have human studies for one condition but only animal data for another.

GH Stimulation

·Human Trials

GHRP-6 reliably stimulates GH release in human studies. It was the reference compound for the GHRP class and has demonstrated reproducible, dose-dependent GH responses across multiple clinical studies.

Limitations: The GH response is well-documented, but GHRP-6 produces the strongest appetite stimulation and hormonal co-elevation of any GHRP, making it less suitable for most clinical applications compared to ipamorelin.

Cardiac Protection

·Animal Studies

Research by Berlanga and colleagues suggests GHRP-6 has cardioprotective effects that operate independently of GH release, mediated through PI3K/Akt survival signaling in cardiac tissue.

Limitations: All cardioprotective data is from animal models (preclinical). Controlled clinical trials evaluating GHRP-6 for cardiac outcomes have not been conducted.

Appetite/GI Function

·Animal Studies

GHRP-6 produces the strongest appetite stimulation of any GH secretagogue through direct ghrelin pathway activation. This effect may be therapeutically relevant in cachexia or appetite-loss conditions.

Limitations: No controlled trials have evaluated GHRP-6 specifically for appetite restoration in clinical populations. The appetite effect is a consistent pharmacological observation, not a validated therapeutic application.

Body Composition

·Animal Studies

GH elevation from GHRP-6 is expected to promote lipolysis and lean mass preservation based on GH physiology, but controlled body composition outcome trials are absent.

Limitations: No controlled trials measuring body composition outcomes. The strong appetite stimulation may partially counteract fat loss effects in practice.

Neuroprotection

·Preclinical

Limited data from animal models (preclinical) suggests GHRP-6 may have neuroprotective properties through GHS-R1a activation in the central nervous system.

Limitations: Extremely limited data. The human evidence base does not include neuroprotection studies. The neuroprotective hypothesis is based on receptor expression patterns and limited animal observations.

Safety and Regulatory Status

FDA Status: Not FDA-approved for any indication.

Availability: On the FDA Category 2 list, meaning licensed pharmacies cannot currently compound it - the compound is restricted from preparation by compounding pharmacies.

Side Effect Profile: Strong appetite stimulation (strongest in GHRP class), significant cortisol elevation, prolactin elevation, facial flushing. All dose-dependent.

The primary effects beyond GH release are strong appetite stimulation, cortisol elevation, and prolactin increase - the most pronounced of any GHRP. Serious adverse events in published studies are rare.

Peptide Structure

Technical molecular data for researchers and clinicians.

Questions and Comparisons

Questions the evidence raises for a GHRP-6 discussion.

Comparison and Related Research

GHRP-6 is most often compared with ipamorelin (most selective, cleanest profile), GHRP-2 (Japan-approved, moderate selectivity), and hexarelin (most potent, CD36 cardiac mechanism).

Head-to-head comparisons

Full research comparisons covering GHRP-6 and another peptide side by side.

GHRP-6 vs Hexarelin

Both produce strong GH release but with different side effects. Hexarelin has cardiac research. GHRP-6 has more hunger. Evidence-graded comparison.

View full comparison

Related compounds

Ipamorelin GHRP-2 Hexarelin CJC-1295 MK-677

Frequently Asked Questions

References

Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.

1.The original characterization of GHRP-6, demonstrating that this synthetic hexapeptide specifically stimulates GH release from pituitary cells both in laboratory settings and in living organisms. This study established the foundation for the entire growth hormone releasing peptide research field.Bowers CY et al., 1984 in Endocrinology. View on PubMed
2.Investigated the wound healing and cytoprotective properties of GHRP-6 in animal models. The study found that GHRP-6 treatment accelerated wound closure, improved tissue remodeling, and produced better cosmetic outcomes compared to untreated wounds.Mendoza Mari Y et al., 2016 in Plast Surg Int. View on PubMed
3.Evaluated the GHRP-6 stimulation test as a diagnostic tool for GH deficiency in children. The study demonstrated that GHRP-6 reliably distinguishes between GH-deficient and normal-secreting individuals, supporting its clinical use as a diagnostic agent.Pombo M et al., 1996 in J Pediatr Endocrinol Metab. View on PubMed
4.Mapped the distribution of the growth hormone secretagogue receptor (GHS-R) across the brain and peripheral tissues. The widespread receptor expression helped explain how compounds like GHRP-6 exert effects beyond simple GH release, including appetite regulation and cardiovascular activity.Guan XM et al., 1997 in Brain Res Mol Brain Res. View on PubMed

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.